Comera Life Sciences Holdings (Comera Life Sciences Holdings) Debt-to-Equity : -0.04 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings Debt-to-Equity?

Comera Life Sciences Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.17 Mil. Comera Life Sciences Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Comera Life Sciences Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-4.22 Mil. Comera Life Sciences Holdings's debt to equity for the quarter that ended in Sep. 2023 was -0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Comera Life Sciences Holdings's Debt-to-Equity or its related term are showing as below:

CMRA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.23 Med: -0.05 Max: 1.06
Current: -0.04

During the past 3 years, the highest Debt-to-Equity Ratio of Comera Life Sciences Holdings was 1.06. The lowest was -0.23. And the median was -0.05.

CMRA's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs CMRA: -0.04

Comera Life Sciences Holdings Debt-to-Equity Historical Data

The historical data trend for Comera Life Sciences Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Comera Life Sciences Holdings Debt-to-Equity Chart

Comera Life Sciences Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Debt-to-Equity

1.06

-0.02

-0.05

Comera Life Sciences Holdings Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial						-0.11	-0.05	-0.05	-0.04	-0.04

Competitive Comparison of Comera Life Sciences Holdings's Debt-to-Equity

For the Biotechnology subindustry, Comera Life Sciences Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Comera Life Sciences Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's Debt-to-Equity falls into.

Comera Life Sciences Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Comera Life Sciences Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.199	+	0.12)	/	-6.247
	=	-0.05

Comera Life Sciences Holdings's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.172	+	0)	/	-4.221
	=	-0.04

Comera Life Sciences Holdings (OTCPK:CMRA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Comera Life Sciences Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Gill Street, Suite 4650, Woburn, MA, USA, 01801

Website

https://www.comeralifesciences.com

Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

Executives

Michael Gerard Campbell	officer: Chief Financial Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
David Soane	10 percent owner	C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney	officer: Chief Scientific Officer	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck	director	C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle	director	585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr.	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt	officer: Chief Business Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman	director, officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni	officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp	10 percent owner	36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065